Panel Discussion: Market Reactogenicity & Trial Design: Balancing Scientific Integrity with Commercial Urgency for Injectables
2:00 pm - Wednesday 28th January 2026
- Why does early recruitment remain a bottleneck, especially for injected therapies in conservative indications like glaucoma?
- How do we design devices and protocols for operators who aren’t traditionally trained in injection procedures? • How do we push back against unrealistic investor timelines and expectations for one-and-done cures?
- What happens when a formulation looks great in vitro but fails due to real-world hurdles like sterilization or inflammatory responses?
